Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3145–3168 of 13,638 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Breast Cancer
Interventions: Collection of blood; Other
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Fargo, North Dakota • Sioux Falls, South Dakota

Conditions: Plaque Type Psorisis
Interventions: Tapinarof Cream 1%, VTAMA®, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 26
States / cities: Scottsdale, Arizona • Bryant, Arkansas • Dublin, California + 20 more

Conditions: Breast Cancer
Interventions: Cardiac MRI; Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 403 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2032
U.S. locations: 66
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Tampa, Florida + 52 more

Conditions: Surgical Site Infection, Skin Cancer, Wound Healing
Interventions: Cyanoacrylate Skin Adhesive, Fast Gut Running Epidermal Suture Closure, Vicryl Rapide Running Epidermal Suture Closure, Prolene Running Epidermal Suture Closure; Device · Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Minneapolis, Minnesota

Conditions: Full-thickness Skin Defects, Degloving Injuries, Crush Injuries, Laceration of Skin, Surgical Wound, Skin Cancer, Cellulitis, Infection, Necrotizing Fasciitis, Gun Shot Wound
Interventions: Control Intervention (Conventional Autograft), Investigational Intervention (RECELL + more widely meshed autograft); Procedure · Device
Lead sponsor: Avita Medical; Industry
Eligibility: 5 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Orange, California + 14 more

Conditions: Breast Cancer
Interventions: limonene containing massage oil; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Skin Cancer
Interventions: Fractionated Laser Resurfacing; Device
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Metastatic Breast Cancer, Breast Tumor, Advanced Gynecologic Cancer
Interventions: Genetic profiling; Genetic
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions: PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 31
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more

Conditions: Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Uterine Corpus Cancer, Uterine Corpus Carcinosarcoma
Interventions: Metformin Hydrochloride, Doxycycline; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Digoxin; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
Interventions: Pembrolizumab, Gemcitabine, Docetaxel, Nab-paclitaxel, Vinorelbine, Irinotecan, Liposomal Doxorubicin; Drug
Lead sponsor: Western Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Goodyear, Arizona

Conditions: Common Warts (Verruca Vulgaris)
Interventions: Candin, Intradermal Solution, Placebo; Drug
Lead sponsor: Nielsen BioSciences, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 18
States / cities: Birmingham, Alabama • Bryant, Arkansas • Fort Smith, Arkansas + 15 more

Conditions: Chemotherapeutic Agent Toxicity, Pain, Peripheral Neuropathy, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Therapy-related Toxicity
Interventions: cryotherapy, questionnaire administration, quality-of-life assessment, management of therapy complications, assessment of therapy complications; Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions: PN+LCNC, PN Only; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • San Antonio, Texas

Conditions: Periodontal Disease, Quality of Life
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer
Interventions: Olaparib, Pembrolizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Breast Cancer, Sedentary Lifestyle
Interventions: Common intervention components for Lifestyle; Behavioral
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions: Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Tamoxifen Citrate, Trastuzumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 3,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 154
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more

Conditions: Metastatic Melanoma, Unresectable Melanoma
Interventions: IO102-IO103, Pembrolizumab; Drug
Lead sponsor: IO Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Orange City, Florida • Orlando, Florida • Buffalo, New York + 1 more

Conditions: Melanoma
Interventions: Temozolomide, Bevacizumab; Drug
Lead sponsor: Mt. Sinai Medical Center, Miami; Other
Eligibility: 18 Years to 90 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: San Francisco, California • Santa Monica, California • Miami Beach, Florida

Conditions: HIV Infection, Mitochondrial Dysfunction
Interventions: Atazanavir/ritonavir, Efavirenz; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Multiple Myeloma
Interventions: survey; Other
Lead sponsor: Carevive Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis, Diffuse Scleroderma, Diffuse Cutaneous Systemic Sclerosis, Diffuse Cutaneous Scleroderma, Progressive Systemic Sclerosis, Progressive Scleroderma, Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma;Progressive, Systemic Sclerosis, Diffuse, Systemic; Sclerosis, Progressive, Scleroderma of Lung, Scleroderma With Pulmonary Involvement, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement, Interstitial Lung Disease, Pulmonary Fibrosis Interstitial
Interventions: Ixazomib; Drug
Lead sponsor: Michael M. Pham; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Scottsdale, Arizona

Search by objective public record fields.

Autoantibodies in Breast Cancer Detection

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

Understanding and Predicting Breast Cancer Events After Treatment

Cyanoacrylate Skin Adhesive After Mohs Surgery or Wide Local Excision

RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction

Human Breast Tissue Bioavailability of Topically Applied Limonene

Mechanisms for Laser-Induced Rejuvenation

Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Candin for the Treatment of Common Warts

Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel

Redes III Patient Navigator Qol Study

Oral Health in Breast Cancer Survivors on Aromatase Inhibitors

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

Developing a Healthy Lifestyle in Breast Cancer Survivors

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring

A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients